About Pain Therapeutics
Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: PTIE
- CUSIP: 69562K10
- Previous Close: $0.59
- 50 Day Moving Average: $0.5871
- 200 Day Moving Average: $1.1676
- 52-Week Range: $0.51 - $3.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.37
- P/E Growth: -0.0200
- Market Cap: $27.00M
- Outstanding Shares: 45,742,000
- Beta: 2.13
- Return on Equity: -68.80%
- Return on Assets: -62.42%
Companies Related to Pain Therapeutics:
- Current Ratio: 10.29%
- Quick Ratio: 10.29%
What is Pain Therapeutics' stock symbol?
Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."
Where is Pain Therapeutics' stock going? Where will Pain Therapeutics' stock price be in 2017?
1 equities research analysts have issued twelve-month target prices for Pain Therapeutics' stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Pain Therapeutics' share price to reach $2.50 in the next year.
When will Pain Therapeutics announce their earnings?
Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Pain Therapeutics stock?
Pain Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.81%) and Gabelli Funds LLC (0.38%).
Who sold Pain Therapeutics stock? Who is selling Pain Therapeutics stock?
Pain Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
Who bought Pain Therapeutics stock? Who is buying Pain Therapeutics stock?
Pain Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Gabelli Funds LLC.
How do I buy Pain Therapeutics stock?
Shares of Pain Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Pain Therapeutics stock cost?
One share of Pain Therapeutics stock can currently be purchased for approximately $0.59.